Filing Flows

Filing Flows › Sarepta Therapeutics (SRPT) › Who owns the stock

Who owns Sarepta Therapeutics (SRPT) stock

299 funds reported Sarepta Therapeutics (SRPT) shares in their latest 13F filings, worth $2.1B in all. The largest holder is BlackRock ($341M). Last quarter 134 funds added to their stakes and 165 cut them.

Largest holders of SRPT (13F)Largest holders of SRPT (13F)BlackRock$341MVanguard Group$254MState Street$160MVanguard Portfolio Management LLC$151MTwo Sigma Investments, LP$82.6MVanguard Capital Management LLC$82.5MFirst Trust Advisors LP$78.5MAQR Capital Management LLC$76.9MGeode Capital Management, LLC$49.8MErste Asset Management GmbH$45.5M

Largest holders (13F)

FundSharesValueChangeQuarter
BlackRock18,994,958$341Mincrease2026-06-30
Vanguard Group11,810,729$254Mincrease2025-12-31
State Street8,916,090$160Mincrease2026-06-30
Vanguard Portfolio Management LLC8,377,470$151Mincrease2026-06-30
Two Sigma Investments, LP4,598,735$82.6Mincrease2026-06-30
Vanguard Capital Management LLC4,591,755$82.5Mincrease2026-06-30
First Trust Advisors LP4,365,951$78.5Mincrease2026-06-30
AQR Capital Management LLC4,325,689$76.9Mdecrease2026-06-30
Geode Capital Management, LLC2,771,758$49.8Mincrease2026-06-30
Erste Asset Management GmbH2,568,945$45.5Mdecrease2026-06-30
Marshall Wace, LLP2,206,022$39.6Mincrease2026-06-30
Morgan Stanley2,202,641$39.6Mdecrease2026-06-30
abrdn2,194,948$39.4Mdecrease2026-06-30
Bank of America2,055,985$36.9Mdecrease2026-06-30
Goldman Sachs Group2,042,501$36.7Mincrease2026-06-30

Sarepta Therapeutics' latest quarter

Sarepta Therapeutics, Q3 2026: revenue $381M (-4% year over year), operating margin -2.4%, net loss $28.5M, operating cash flow $60.0M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most SRPT stock?

By the latest 13F filings: BlackRock ($341M); Vanguard Group ($254M); State Street ($160M); Vanguard Portfolio Management LLC ($151M); Two Sigma Investments, LP ($82.6M).

What is the short interest in SRPT?

22,330,342 shares were sold short at the 2026-10-15 settlement, -1.99% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.